Advanced search
Publication Cover
Clinical, Cosmetic and Investigational Dermatology Volume 16, 2023 - Issue
Submit an article Journal homepage
122
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Herpes Zoster Ophthalmicus Clinical Presentation and Risk Factors for Lesion Recovery

Zupeng XiaoDepartment of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-6633-8392View further author information
ORCID Icon,
Hanyi WuDepartment of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of ChinaView further author information
,
Xin ChenDepartment of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of ChinaView further author information
,
Xiaoli ChenDepartment of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of ChinaView further author information
,
Rentao YuDepartment of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of ChinaView further author information
&
Aijun ChenDepartment of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of ChinaCorrespondence[email protected] [email protected]
View further author information
Pages 3767-3773 | Received 15 Oct 2023, Accepted 17 Dec 2023, Published online: 28 Dec 2023

References

  • Schmader K. Herpes Zoster. Ann Intern Med. 2018;169:897. doi:10.7326/L18-0558
  • Sauerbrei A. Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections. Eur J Clin Microbiol Infect Dis. 2016;35:723–734. doi:10.1007/s10096-016-2605-0
  • Ting DSJ, Ghosh N, Ghosh S. Herpes zoster ophthalmicus. BMJ. 2019;364:k5234. doi:10.1136/bmj.k5234
  • Szeto SK, Chan TC, Wong RL, Ng AL, Li EY, Jhanji V. Prevalence of ocular manifestations and visual outcomes in patients with herpes zoster ophthalmicus. Cornea. 2017;36:338–342. doi:10.1097/ICO.0000000000001046
  • Yawn BP, Wollan PC, St Sauver JL, Butterfield LC. Herpes zoster eye complications: rates and trends. Mayo Clin Proc. 2013;88:562–570. doi:10.1016/j.mayocp.2013.03.014
  • Johnson RW, Bouhassira D, Kassianos G, Leplège A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8:37. doi:10.1186/1741-7015-8-37
  • Liesegang TJ. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology. 2008;115:S3–12.
  • Werner RN, Steinhorst NI, Nast A, Pleyer U. Diagnostik und Management des Herpes zoster ophthalmicus. Ophthalmology. 2017;114:959–972. doi:10.1007/s00347-017-0562-3
  • Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341–1349. doi:10.4065/82.11.1341
  • Kaufman SC. Anterior segment complications of herpes zoster ophthalmicus. Ophthalmology. 2008;115(2 Suppl):S24–32. PMID: 18243929. doi:10.1016/j.ophtha.2007.10.010
  • Borkar DS, Tham VM, Esterberg E, et al. Incidence of herpes zoster ophthalmicus: results from the pacific ocular inflammation study. Ophthalmology. 2013;120:451–456. doi:10.1016/j.ophtha.2012.09.007
  • Lam FC, Law A, Wykes W. Herpes zoster ophthalmicus. BMJ. 2009;339:b2624.
  • Davies EC, Pavan-Langston D, Chodosh J. Herpes zoster ophthalmicus: declining age at presentation. Br J Ophthalmol. 2016;100:312–314. doi:10.1136/bjophthalmol-2015-307157
  • Cifuentes-González C, Rojas-Carabali W, Fonseca-Mora MA, Mejia-Salgado G, Reyes-Guanes J, de-la-Torre A. Colombian ocular infectious epidemiology study: herpes zoster ophthalmicus prevalence and sociodemographic characterization, 2015–2019. Int J Infect Dis. 2022;116:27–33. doi:10.1016/j.ijid.2021.12.332
  • Miller AE. Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology. 1980;30:582–587. doi:10.1212/WNL.30.6.582
  • Cunningham AL, Lal H, Kovac M, et al.; ZOE-70 Study Group. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 375;2016:1019–1032. doi:10.1056/NEJMoa1603800
  • Lal H, Cunningham AL, Godeaux O, et al.; ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 372;2015:2087–2096. doi:10.1056/NEJMoa1501184
  • Whitley RJ, Cloud G, Gruber W, et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a Phase II study. National institute of allergy and infectious diseases collaborative antiviral study group. J Infect Dis. 1997;175:1080–1086. doi:10.1086/516445
  • Han Y, Zhang J, Chen N, He L, Zhou M, Zhu C, Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2013;3:CD005582. doi:10.1002/14651858.CD005582.pub4
  • Li A, Tandon A, Dinkin M, Oliveira C. The use of systemic steroids in the treatment of herpes zoster ophthalmicus-related ophthalmoplegia: case report and case meta-analysis. Am J Ophthalmol. 2021;223:241–245. doi:10.1016/j.ajo.2020.10.022
  • Pavan-Langston D. Herpes zoster antivirals and pain management. Ophthalmology. 2008;115(2 Suppl):S13–20. PMID: 18243927. doi:10.1016/j.ophtha.2007.10.012
  • Miyoshi H, Hirotsuji N, Kino T, Katsu K. Interferon alpha gel for herpes zoster. Dermatology. 1997;194:306. doi:10.1159/000246139

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.